Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our decentralized manufacturing strategy and rapid release testing, enables delivery ...

Intellia has leveraged its expertise in Crispr/Cas9 gene editing to advance a pipeline of in vivo and ex vivo therapies for diseases with high unmet medical needs. We believe Intellia's proprietary ...

Carrie Buck was raped, labeled an “imbecile,” and sterilized by order of the state — all in the name of genetic progress.

Researchers engineered a new therapeutically enhanced, naturally derived particle for powerful gene therapies to tackle our ...

Cardiovascular disease and kidney disease are two of the most urgent issues in global public health. In the United States ...

One of the biggest challenges facing biologic drug developers are varying efficacy and the dangers of side effects.

A research team led by Associate Professor Makoto Ikeya in the Department of Clinical Application at Kyoto University has ...

Princeton University awarded honorary degrees to Omar M. Yaghi, Daniel Chee Tsui, Nancy Weiss Malkiel, Joshua ...

Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and ...

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...